Generic selectors

Exact matches only

Exact matches only

Search in title

Search in title

Search in content

Search in content

Search in excerpt

Post Type Selectors

Hidden

Hidden

Filter by Categories

BioBlast

BioBlast®

Biosimilars Deals

Biosimilars Deals 2023

Diversity

Diversity

Masterclasses

Masterclasses

Other Podcasts

Other Podcasts

Other Updates

Other Updates

Our Awards

Our Awards

Patent Litigation

Patent Litigation

Patents

Patents

PipCast

PipCast®

PTE

PTE

Trade Marks

Trade Marks

Webinars

Webinars

Our Awards
Our Capabilities
Our People
Blog
BioBlast®
E-Books
Webinars
Diversity
Careers
Contact Us

Home / News / BioBlast®

Imraldi dominates 46% share of EU AmAb biosimilar market

Jun 4, 2019

Samsung BioLogics announces Imraldi® dominates 46% share in European adalimumab biosimilar market.

LinkedIn

Print Page Mail Article

View all BioBlast® Updates

Product specific reports based on extracts from our BioBlast® database

adalimumab | Humira® | AbbVie

aflibercept | Eylea® | Regeneron

bevacizumab | Avastin® | Roche/Genentech

cetuximab | Erbitux® | BMS/Merck

darbepoetin | Aranesp® | Amgen

denosumab | Prolia®/Xgeva® | Amgen

dupilumab | Dupixent® | Sanofi-Aventis

eculizumab | Soliris® | Alexion

etanercept | Enbrel® | Amgen

faricimab | Vabysmo® | Roche

filgrastim (GCSF) | Neupogen® | Amgen

golimumab | Simponi® | Janssen

guselkumab | Tremfya® | Janssen

infliximab | Remicade® | Johnson & Johnson

ixekizumab | Taltz® | Eli Lilly

natalizumab | Tysabri® | Biogen/Elan

omalizumab | Xolair® | Genentech / Novartis

pegfilgrastim | Neulasta® | Amgen

pembrolizumab | Keytruda® | Merck

pertuzumab | Perjeta® | Roche

ranibizumab | Lucentis® | Genentech

regdanvimab | Regkirona® | Celltrion

risankizumab | Skyrizi® | AbbVie

rituximab | Rituxan®/MabThera® | Genentech/Biogen

secukinumab | Cosentyx® | Novartis

tocilizumab | Actemra® | Roche

trastuzumab | Herceptin® | Roche/Genentech

ustekinumab | Stelara® | Johnson & Johnson/Janssen

View latest BioBlast® updates

Biosimilars Deals

SUBSCRIBE TO PEARCE IP

Sign up to receive the latest life sciences industry news

Receive our weekly BioBlast®, regular life sciences Industry News and other Pearce IP updates straight to your inbox.

SUBSCRIBE

2305 Pearce IP Team Collage

2305 Pearce IP Team Collage

Our People
Our Capabilities
News
Blog
BioBlast®
Contact Us

Copyright © Pearce IP. All Rights Reserved. Privacy Statement

Manage Cookie Consent

We use cookies to optimise our website and our service.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options Manage services Manage vendors Read more about these purposes

Preferences

{title} {title} {title}